dexamethasone + minocycline + ranibizumab + verteporfin

This is a combination therapy consisting of four active pharmaceutical ingredients: - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties. It acts by binding to the glucocorticoid receptor, modulating gene expression, and suppressing inflammatory mediators. - **Minocycline** is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It also has anti-inflammatory and neuroprotective effects. - **Ranibizumab** is a recombinant humanized monoclonal antibody fragment (Fab) that binds to vascular endothelial growth factor A (VEGF-A), inhibiting its activity and thereby reducing abnormal blood vessel growth and leakage in the eye. - **Verteporfin** is a benzoporphyrin derivative used as a photosensitizer in photodynamic therapy. Upon activation by nonthermal red light in the presence of oxygen, it generates reactive oxygen species that damage neovascular endothelium, leading to vessel occlusion. This specific four-drug combination does not correspond to an approved or widely studied regimen; however, combinations involving ranibizumab plus verteporfin (with or without dexamethasone) have been investigated for neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy[1][2][3]. The addition of minocycline would theoretically provide further anti-inflammatory or neuroprotective benefit but lacks direct clinical trial evidence as part of this exact quadruple regimen.